Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $19 | $13 | $3 | $7 |
| % Growth | 43.3% | 304.4% | -55.2% | – |
| Cost of Goods Sold | $8 | $7 | $5 | $12 |
| Gross Profit | $11 | $6 | -$2 | -$5 |
| % Margin | 59.5% | 48.1% | -64.2% | -63.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $9 | $7 | $8 | $12 |
| SG&A Expenses | $9 | $7 | $8 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $3 | $1 |
| Operating Expenses | $10 | $8 | $10 | $13 |
| Operating Income | $1 | -$1 | -$13 | -$17 |
| % Margin | 7.3% | -10.8% | -388.4% | -238.8% |
| Other Income/Exp. Net | -$2 | -$2 | $7 | -$2 |
| Pre-Tax Income | -$0 | -$3 | -$5 | -$19 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$8 | -$3 | $6 | -$18 |
| % Margin | -41.4% | -25.3% | 173.9% | -254.7% |
| EPS | -0 | -0.033 | -913.37 | -93,864,830.67 |
| % Growth | 99.4% | 100% | 100% | – |
| EPS Diluted | -0 | -0.033 | -913.37 | -93,864,830.67 |
| Weighted Avg Shares Out | 32,826 | 9,992 | 1 | 0 |
| Weighted Avg Shares Out Dil | 32,826 | 9,992 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $3 | $10 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $1 | -$0 | -$1 | -$8 |
| % Margin | 7.8% | -2.4% | -39.2% | -116.8% |